ArticleBone marrow transplantation2020
Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia.
Abstract readLetter
In one paragraph
Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Pooled it
- Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.Clinical epigenetics · 2025Trial
- Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2021Trial
- Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy.Journal of managed care & specialty pharmacy · 2026Article
- The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations.Transplantation and cellular therapy · 2026Article
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.Molecular therapy. Oncology · 2026Review
- Rare acute myeloid leukemia harboring BCR/ABL1 (P210), AML1-MDS1/EVI1, and AML1/EAP: case report and literature review.Frontiers in oncology · 2026Article
- Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls.Therapeutic advances in hematology · 2026Article
- Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome.Haematologica · 2025Article
- Review
- Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective.Frontiers in oncology · 2025Article
- Review
- Transplant Eligible and Ineligible Elderly Patients with AML-A Genomic Approach and Next Generation Questions.Biomedicines · 2024Review
- The impact of granulocyte colony-stimulating factor and decitabine-containing conditioning in myelodysplastic syndrome patients with iron overload undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study.Therapeutic advances in hematology · 2024Article
- Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation.Clinical case reports · 2023Article
- Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.International journal of hematology · 2023Review
- Current status and prospects of hematopoietic stem cell transplantation in China.Chinese medical journal · 2022Review
- Decitabine-Intensified Modified Busulfan/Cyclophosphamide Conditioning Regimen Improves Survival in Acute Myeloid Leukemia Patients Undergoing Related Donor Hematopoietic Stem Cell Transplantation: A Propensity Score Matched Analysis.Frontiers in oncology · 2022Article
- Low-Dose 5-Aza and DZnep Alleviate Acute Graft-Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Yunju MaDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Changju QuDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Haiping DaiDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Jia YinDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Zheng LiDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Jia ChenDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Huiying QiuDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Aining SunDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Miao MiaoDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Chengcheng FuDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Zhengming JinDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Xiaming ZhuDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China.
Depei WuDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China. drwudepei@163.com.
Xiaowen TangDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, 215006, Suzhou, China. xwtang1020@163.com.
First Affiliated Hospital of Soochow University · CNGuangzhou Blood Center · CNSoochow University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteDecitabineHumansRecurrenceTransplantation, HomologousDecitabine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.